[Cardiologic follow up of an oncologic patient].
Recent progress in cancer therapy has dramatically modified the course and prognosis of some malignancies. Chemo and radiotherapy, along with newer targeted treatments, are given to control symptoms, postpone relapse, or attempt cure. However, many of these regimens are associated with adverse cardiovascular effects such as impaired left ventricular function, myocardial ischemia, hypertension, and arrhythmia. Awareness of potential cardiotoxicity is important, as it may allow practitioners to recognize early signs of cardiac complications and to adapt therapy in order to limit detrimental effects. Diagnosis of cardiovascular complications may iustify the introduction of cardiologic therapies, and may require the reassessment of risk/benefit ratios related to specific cancer therapy. Screening and follow up strategies are proposed.
Zaugg Longchamp
Danielle
D
Service de cardiologie, Département de médecine interne, CHUV, 1011 Lausanne. danielle.zaugg@chuv.ch
Zaman
Khalil
K
Aebischer
Nicole
N
D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D006331:Heart Diseases / Q000453:epidemiology* / Q000209:etiology; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D011878:Radiotherapy / Q000009:adverse effects; D000068878:Trastuzumab; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab